JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis

Cancer Research

Volumn 76, Issue 4, 2016, Pages 831-843

  Li, Na ^a   Dhar, Shilpa S ^a   Chen, Tsai Yu ^a   Kan, Pu Yeh ^a   Wei, Yongkun ^a   Kim, Jae Hwan ^a,d   Chan, Chia Hsin ^a,e   Lin, Hui Kuan ^a   Hung, Mien Chie ^a,b,c   Lee, Min Gyu ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Seoul National University   (South Korea)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; JARID1D PROTEIN; MATRILYSIN; MESSENGER RNA; ONCOPROTEIN; STROMELYSIN; TRANSCRIPTION FACTOR SLUG; TUMOR MARKER; UNCLASSIFIED DRUG; HISTONE DEMETHYLASE; KDM5D PROTEIN, HUMAN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE REPRESSION; GENETIC ASSOCIATION; MALE; METASTASIS; MMP1 GENE; MMP2 GENE; MMP3 GENE; MMP7 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN FUNCTION; SLUG GENE; TUMOR INVASION; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HISTONE DEMETHYLASES; HUMANS; MALE; MICE; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TRANSFECTION;

EID: 84960461149     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0906     Document Type: Article

References (53)

1. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. Highresolution profiling of histone methylations in the human genome. Cell 2007;129:823-37.
2. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007;448:553-60.
3. Gu B, Lee MG. Histone H3 lysine 4 methyltransferases and demethylases in self-renewal and differentiation of stem cells. Cell Biosci 2013;3:39.
4. Shi Y, Whetstine JR. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell 2007;25:1-14.
5. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007;8:307-18.
6. Ruthenburg AJ, Allis CD, Wysocka J.Methylation of lysine 4 on histone H3: intricacy ofwriting and reading a single epigenetic mark. Mol Cell 2007;25: 15-30.
7. Lee MG, Norman J, Shilatifard A, Shiekhattar R. Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb-like protein. Cell 2007;128:877-87.
8. Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 2007;25:801-12.
9. Christensen J, Agger K, Cloos PA, Pasini D, Rose S, Sennels L, et al. RBP2 Belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 2007;128:1063-76.
10. Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L,Huarte M, Qi HH, et al. The Xlinkedmental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 2007;128:1077-88.
11. Tahiliani M, Mei P, Fang R, Leonor T, Rutenberg M, Shimizu F, et al. The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 2007;447:601-5.
12. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005; 437:432-5.
13. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119:941-53.
14. Stahl PR, Kilgue A, Tennstedt P, Minner S, Krohn A, Simon R, et al. Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. Prostate 2012;72:898-903.
15. Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P, Dahiya R. Deletion of Y-chromosome specific genes in human prostate cancer. J Urol 2000;163: 1339-42.
16. Wallrapp C, Hahnel S, Boeck W, Soder A, Mincheva A, Lichter P, et al. Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis. Int J Cancer 2001;91:340-4.
17. Bianchi NO, Richard SM, Pavicic W. Y chromosome instability in testicular cancer. Mutat Res 2006;612:172-88.
18. Hunter S, Gramlich T, Abbott K, Varma V. Y chromosome loss in esophageal carcinoma: An in situ hybridization study. Genes Chromosomes Cancer 1993;8:172-7.
19. Minner S, Kilgue A, Stahl P, Weikert S, Rink M, Dahlem R, et al. Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology 2010;42:356-9.
20. Vijayakumar S, Garcia D, Hensel CH, Banerjee M, Bracht T, Xiang R, et al. The human Y chromosome suppresses the tumorigenicity of PC-3, a human prostate cancer cell line, in athymic nude mice. Genes Chromosomes Cancer 2005;44:365-72.
21. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet 2014;46:624-8.
22. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest 2013;123:5231-46.
23. Dhar SS, Alam H, Li N, Wagner KW, Chung J, Ahn YW, et al. Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. J Biol Chem 2014;289: 7483-96.
24. Kim JH, Sharma A, Dhar SS, Lee SH, Gu B, Chan CH, et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 2014;74:1705-17.
25. Dhar SS, Lee SH, Kan PY, Voigt P, Ma L, Shi X, et al. Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4. Genes Dev 2012;26:2749-62.
26. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol 2009;10:R25.
27. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008;9:R137.
28. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol 2011;12:R83.
29. Nemeth JA, Harb JF, Barroso U, Jr., He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-93.
30. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, et al. Stat3 promotes metastatic progression of prostate cancer.AmJ Pathol 2008;172: 1717-28.
31. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
32. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147:992-1009.
33. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29.
34. Miller SA, Mohn SE, Weinmann AS. Jmjd3 and UTX play a demethylaseindependent role in chromatin remodeling to regulate T-box family member-dependent gene expression. Mol Cell 2010;40:594-605.
35. Wang C, Lee JE, Cho YW, Xiao Y, Jin Q, Liu C, et al. UTXregulates mesoderm differentiation of embryonic stem cells independent of H3K27 demethylase activity. Proc Natl Acad Sci U S A 2012;109:15324-9.
36. Shpargel KB, Sengoku T, Yokoyama S, Magnuson T. UTX and UTY demonstrate histone demethylase-independent function in mouse embryonic development. PLoS Genet 2012;8:e1002964.
37. Grasso CS,WuYM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
38. Oram SW, Liu XX, Lee TL, Chan WY, Lau YF. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC Cancer 2006;6:154.
39. Murakami S, Chishima S, Uemoto H, Sakamoto E, Sato T, Kurabe N, et al. The male-specific factor Sry harbors an oncogenic function. Oncogene 2014;33:2978-86.
40. Walport LJ, Hopkinson RJ, Vollmar M, Madden SK, Gileadi C, Oppermann U, et al. Human UTY(KDM6C) is amale-specific N-methyl lysyl demethylase. J Biol Chem 2014;289:18302-13.
41. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010;70:61-9.
42. Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase upregulated in prostate cancer. Proc Natl Acad Sci U S A 2007;104:19226-31.
43. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66:11341-7.
44. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
45. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999;147:631-44.
46. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139: 1861-72.
47. Ota I, Li XY, Hu Y, Weiss SJ. Induction of a MT1-MMP and MT2-MMPdependent basementmembrane transmigration program in cancer cells by Snail1. Proc Natl Acad Sci U S A 2009;106:20318-23.
48. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010;16:286-94.
49. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012;72:3091-104.
50. Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, et al. Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep 2014;6:868-77.
51. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A 2012;109:E3367-76.
52. Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, et al. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res 2012;72:810-20.
53. Wu PC, Lu JW, Yang JY, Lin IH, Ou DL, Lin YH, et al. H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis. Cancer Res 2014;74:7333-43.